FDFT1依赖肿瘤免疫微环境促进结肠癌细胞的生长

罗娜; 张大鹏; 缪洪明; 代荣阳

doi:10.16016/j.1000-5404.202106129

您当前的位置：

首页 >

文章列表页 >

FDFT1依赖肿瘤免疫微环境促进结肠癌细胞的生长

基础医学 | 更新时间：2026-01-09

- FDFT1依赖肿瘤免疫微环境促进结肠癌细胞的生长
- Farnesyl-diphosphate farnesyltransferase 1 promotes growth of colorectal cancer cells with dependence on tumor immune microenvironment
- 第三军医大学学报 2021年43卷第24期页码：2648-2655
- 作者机构：
  
  1.646000 四川泸州，西南医科大学基础医学院
  2.400038 重庆，陆军军医大学(第三军医大学)基础医学院生物化学与分子生物学教研室
- 作者简介：
  
  [ 代荣阳，E-mail: dryrun2502@163.com DAI Rongyang, E-mail: dryrun2502@163.com
- 基金信息：
  
  国家自然科学基金面上项目(81872028)
- DOI：10.16016/j.1000-5404.202106129
  中图分类号： R345;R730.23;R735.35
- 收稿：2021-06-17，
  
  修回：2021-09-22，
  
  纸质出版：2021-12-30
- 稿件说明：
移动端阅览
罗娜, 张大鹏, 缪洪明, 等. FDFT1依赖肿瘤免疫微环境促进结肠癌细胞的生长[J]. 第三军医大学学报, 2021,43(24):2648-2655.

Na LUO, Dapeng ZHANG, Hongming MIAO, et al. Farnesyl-diphosphate farnesyltransferase 1 promotes growth of colorectal cancer cells with dependence on tumor immune microenvironment[J]. Journal of Third Military Medical University, 2021, 43(24): 2648-2655.
罗娜, 张大鹏, 缪洪明, 等. FDFT1依赖肿瘤免疫微环境促进结肠癌细胞的生长[J]. 第三军医大学学报, 2021,43(24):2648-2655. DOI： 10.16016/j.1000-5404.202106129.

Na LUO, Dapeng ZHANG, Hongming MIAO, et al. Farnesyl-diphosphate farnesyltransferase 1 promotes growth of colorectal cancer cells with dependence on tumor immune microenvironment[J]. Journal of Third Military Medical University, 2021, 43(24): 2648-2655. DOI： 10.16016/j.1000-5404.202106129.

摘要

目的

研究法呢基二磷酸酯法呢基转移酶1 (farnesyl-diphosphate farnesyltransferase 1，FDFT1)对结肠癌(colorectal cancer，CRC)细胞MC-38体内体外生长的影响。

方法

通过GEPIA数据库分析275例CRC样本和349例正常组织样本中FDFT1的表达量，通过数据库分析人CRC中FDFT1的免疫组化表达水平。使用慢病毒介导的短发夹RNA(short hairpin RNA，shRNA)构建FDFT1沉默的CRC细胞系MC-38，得到稳定低表达FDFT1的MC-38细胞系(sh-FDFT1组)和空载对照细胞系(sh-NC组)，Western blot、RT-qPCR验证敲低效果。CCK-8实验、流式细胞术、Transwell实验分别观察敲低FDFT1对MC-38细胞增殖、凋亡、迁移能力的影响。采用C57BL/6小鼠、重度免疫缺陷NCG小鼠构建CRC腹腔种植转移模型，利用C57BL/6小鼠构建皮下移植瘤模型，14 d后观察沉默FDFT1对小鼠肿瘤生长情况的影响。

结果

数据库分析结果显示CRC组织中FDFT1的表达较正常组织高(

0.05)，免疫组化结果显示CRC病人FDFT1高表达。沉默FDFT1对MC-38细胞增殖、凋亡及迁移均没有明显影响；在C57BL/6小鼠CRC腹腔种植转移模型和皮下移植瘤模型中均发现沉默FDFT1后显著抑制肿瘤生长(

0.05)。NCG小鼠腹腔种植转移模型显示沉默FDFT1后肿瘤生长没有差异(

0.05)。

结论

FDFT1在体内促进CRC细胞生长依赖于肿瘤免疫微环境。

Abstract

Objective

To investigate the effects of farnesyl-diphosphate

farnesyltransferase 1 (FDFT1) on the growth of colorectal cancer (CRC) cell line MC-38

in vitro

and in mouse models of colorectal peritoneal metastasis and xenograft tumor.

Methods

The expression of FDFT1 in 275 CRC samples and 349 normal tissue samples

as well as the immunohistochemical expression level of FDFT1 in human CRC tissues were analyzed using online databases Gene Expression Profiling Interactive Analysis (GEPIA) and the Human Protein Atlas

respectively. FDFT1-silenced CRC cell line MC-38 was constructed by lentivirus-mediated short hairpin RNA (shRNA) to obtain stable cells with low expression of FDFT1 (sh-FDFT1)

and blank control cells (sh-NC) was also constructed. The knockdown effect was subsequently verified by Western blotting and RT-qPCR. Cell counting kit-8 (CCK-8) assay

flow cytometry and transwell assay were performed to observe the effects of FDFT1 knockdown on the proliferation

apoptosis and migration of MC-38 cells

respectively. In addition

intraperitoneal implantation models of colorectal cancer were established using C57BL/6 mice and severe immunodeficient NCG mice

and subcutaneous transplantation tumor model was also constructed using C57BL/6 mice. The effects of FDFT1 silencing on tumor growth

in vivo

were observed in 14 d after transplantation.

Results

Database analysis showed that FDFT1 expression was higher in CRC tissues than normal tissues (

0.05)

and immunohistochemical results also confirmed that FDFT1 was highly expressed in CRC tissues. There were no significant alterations in the proliferation

apoptosis and migration of MC-38 cells after knockdown of FDFT1. Although FDFT1 silencing obviously inhibited the tumor growth in both intraperitoneal implantation and subcutaneous xenograft models of CRC in C57BL/6 mice (

0.05)

the colorectal peritoneal metastasis model of NCG mice presented no difference in tumor growth after silenci

ng FDFT1 (

0.05).

Conclusion

FDFT1 depends on the tumor immune microenvironment in the promotion of the growth of CRC cells

in vivo

关键词

Keywords

references

BRAY F, FERLAY J, SOERJOMATARAM I, et al . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J ] . CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.

DEKKER E, REX D K. Advances in CRC prevention: screening and surveillance[J]. Gastroenterology, 2018, 154(7): 1970-1984. DOI: 10.1053/j.gastro.2018.01.069.

PAVLOVA N N, THOMPSON C B. The emerging hallmarks of cancer metabolism[J]. Cell Metab, 2016, 23(1): 27-47. DOI: 10.1016/j.cmet.2015.12.006.

MIAO H M, OU J J, PENG Y, et al . Macrophage ABHD5 promotes colorectal cancer growth by suppressing spermidine production by SRM[J ] . Nat Commun, 2016, 7: 11716. DOI: 10.1038/ncomms11716.

XIANG W, SHI R, KANG X, et al . Monoacylglycerol lipase regulates cannabinoid receptor 2-dependent macrophage activation and cancer progression[J ] . Nat Commun, 2018, 9(1): 2574. DOI: 10.1038/s41467-018-04999-8.

ZHANG D P, SHI R C, XIANG W, et al . The Agpat4/LPA axis in colorectal cancer cells regulates antitumor responses via p38/p65 signaling in macrophages[J ] . Signal Transduct Target Ther, 2020, 5(1): 24. DOI: 10.1038/s41392-020-0117-y.

GELISSEN I C, BROWN A J. An overview of cholesterol homeostasis[J]. Methods Mol Biol, 2017, 1583: 1-6. DOI: 10.1007/978-1-4939-6875-6_1.

LUO J, YANG H, SONG B L. Mechanisms and regulation of cholesterol homeostasis[J]. Nat Rev Mol Cell Biol, 2020, 21(4): 225-245. DOI: 10.1038/s41580-019-0190-7.

HA N T, LEE C H. Roles of farnesyl-diphosphate farnesyltransferase 1 in tumour and tumour microenvironments[J]. Cells, 2020, 9(11): E2352. DOI: 10.3390/cells9112352.

DO R, KISS R S, GAUDET D, et al . Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway[J ] . Clin Genet, 2009, 75(1): 19-29. DOI: 10.1111/j.1399-0004.2008.01099.x.

TVZMENŞ, HOSTETTER G, WATANABE A, et al . Characterization of farnesyl diphosphate farnesyl transferase 1 (FDFT1) expression in cancer[J ] . Per Med, 2019, 16(1): 51-65. DOI: 10.2217/pme-2016-0058.

ZHANG L, WANG I M, SOLBAN N, et al . Comprehensive investigation of T and B cell receptor repertoires in an MC38 tumor model following murine anti-PD-1 administration[J ] . Mol Med Rep, 2020, 22(2): 975-985. DOI: 10.3892/mmr.2020.11169.

EFREMOVA M, RIEDER D, KLEPSCH V, et al . Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution[J ] . Nat Commun, 2018, 9(1): 32. DOI: 10.1038/s41467-017-02424-0.

CORBETT T H, GRISWOLD D P Jr, ROBERTS B J, et al . Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure[J ] . Cancer Res, 1975, 35(9): 2434-2439.

THAKUR C, CHEN F. Connections between metabolism and epigenetics in cancers[J]. Semin Cancer Biol, 2019, 57: 52-58. DOI: 10.1016/j.semcancer.2019.06.006.

AL BANDAR M H, KIM N K. Current status and future perspectives on treatment of liver metastasis in colorectal cancer (Review)[J]. Oncol Rep, 2017, 37(5): 2553-2564. DOI: 10.3892/or.2017.5531.

BRUSSELMANS K, TIMMERMANS L, VAN DE SANDE T, et al . Squalene synthase, a determinant of raft-associated cholesterol and modulator of cancer cell proliferation[J ] . J Biol Chem, 2007, 282(26): 18777-18785. DOI: 10.1074/jbc.M611763200.

KUZU O F, NOORY M A, ROBERTSON G P. The role of cholesterol in cancer[J]. Cancer Res, 2016, 76(8): 2063-2070. DOI: 10.1158/0008-5472.CAN-15-2613.

FUKUMA Y, MATSUI H, KOIKE H, et al . Role of squalene synthase in prostate cancer risk and the biological aggressiveness of human prostate cancer[J ] . Prostate Cancer Prostatic Dis, 2012, 15(4): 339-345. DOI: 10.1038/pcan.2012.14.

ZHENG L, LI L, LU Y, et al . SREBP2 contributes to cisplatin resistance in ovarian cancer cells[J ] . Exp Biol Med (Maywood), 2018, 243(7): 655-662. DOI: 10.1177/1535370218760283.

WENG M L, CHEN W K, CHEN X Y, et al . Fasting inhibits aerobic glycolysis and proliferation in colorectal cancer via the Fdft1-mediated AKT/mTOR/HIF1α pathway suppression[J ] . Nat Commun, 2020, 11(1): 1869. DOI: 10.1038/s41467-020-15795-8.

DEHGHANI M, SAMANI Z, ABIDI H, et al . Relationship of SNP rs2645429 in farnesyl-diphosphate farnesyltransferase 1 gene promoter with susceptibility to lung cancer[J ] . Int J Genomics, 2018, 2018: 4863757. DOI: 10.1155/2018/4863757.

STÄTTERMAYER A F, RUTTER K, BEINHARDT S, et al . Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C[J ] . Liver Int, 2014, 34(3): 388-395. DOI: 10.1111/liv.12269.

MVLLER M F, IBRAHIM A E, ARENDS M J. Molecular pathological classification of colorectal cancer[J]. Virchows Arch, 2016, 469(2): 125-134. DOI: 10.1007/s00428-016-1956-3.

GALON J, BRUNI D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies[J]. Nat Rev Drug Discov, 2019, 18(3): 197-218. DOI: 10.1038/s41573-018-0007-y.

WU T, DAI Y. Tumor microenvironment and therapeutic response[J]. Cancer Lett, 2017, 387: 61-68. DOI: 10.1016/j.canlet.2016.01.043.

BOLOURI H. Network dynamics in the tumor microenvironment[J]. Semin Cancer Biol, 2015, 30: 52-59. DOI: 10.1016/j.semcancer.2014.02.007.

BADER J E, VOSS K, RATHMELL J C. Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy[J]. Mol Cell, 2020, 78(6): 1019-1033. DOI: 10.1016/j.molcel.2020.05.034.

CARDOSO D, PERUCHA E. Cholesterol metabolism: a new molecular switch to control inflammation[J]. Clin Sci (Lond), 2021, 135(11): 1389-1408. DOI: 10.1042/CS20201394.

CHOI C, FINLAY D K. Diverse immunoregulatory roles of oxysterols-the oxidized cholesterol metabolites[J]. Metabolites, 2020, 10(10): E384. DOI: 10.3390/metabo10100384.

KOPECKA J, GODEL M, RIGANTI C. Cholesterol metabolism: At the cross road between cancer cells and immune environment[J]. Int J Biochem Cell Biol, 2020, 129: 105876. DOI: 10.1016/j.biocel.2020.105876.

MA L Q, WANG L, NELSON A T, et al . 27-Hydroxycholesterol acts on myeloid immune cells to induce T cell dysfunction, promoting breast cancer progression[J ] . Cancer Lett, 2020, 493: 266-283. DOI: 10.1016/j.canlet.2020.08.020.

BAEK A E, YU Y A, HE S S, et al . The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells[J ] . Nat Commun, 2017, 8(1): 864. DOI: 10.1038/s41467-017-00910-z.

BAUMANN T, DUNKEL A, SCHMID C, et al . Regulatory myeloid cells paralyze T cells through cell-cell transfer of the metabolite methylglyoxal[J ] . Nat Immunol, 2020, 21(5): 555-566. DOI: 10.1038/s41590-020-0666-9.

HUI L, CHEN Y. Tumor microenvironment: Sanctuary of the devil[J]. Cancer Lett, 2015, 368(1): 7-13. DOI: 10.1016/j.canlet.2015.07.039.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

小鼠THBS1基因敲除改善内脏脂肪免疫微环境并抑制结直肠癌腹腔种植转移

PYCR1在结肠癌中的表达及对细胞的增殖、侵袭及迁移的影响

吴茱萸碱通过NF-κB-p65信号通路抑制人结肠癌细胞SW480的迁移和侵袭

SOX15基因对Caco2结肠癌细胞增殖、凋亡及迁移侵袭的影响

巨噬细胞在结肠癌CT-26细胞获得性5-FU耐药中的作用